Communication - Press  •  Members

CILcare Announces Strategic Partnership to Pioneer 3D Bioprinted Inner Ear Organoids

CILcare joins forces with CTIBIOTECH and SATT AxLR to develop the world’s first 3D bioprinted inner ear organoids for hearing research.

We are thrilled to share exciting news from FACCNE member, CILcare, a global leader in hearing disorders research. CILcare has joined forces with CTIBIOTECH and SATT AxLR to launch the OrgaEar Project, an ambitious initiative to develop the world’s first 3D bioprinted inner ear organoids designed for drug screening in hearing disorders.

This groundbreaking collaboration represents a major step forward in the quest to better understand and treat hearing loss. By combining cutting-edge bioprinting technology with cell-based models, the partners aim to provide a highly advanced, non-animal alternative for therapeutic research, positioning themselves at the forefront of a rapidly growing bioassay market projected to reach €28 billion by 2028.

Here is the press release for further information: https://www.cilcare.com/2025/10/10/development-of-the-first-inner-ear-organoids-by-3d-bioprinting-for-pharmacological-screening-in-hearing-disorders-ctibiotech-announces-strategic-agreement-with-satt-axlr-and-cilcare/